科利吉安公司以6.5亿美元的价格购买了AZSTARYS ADHD药物, 将其产品组合增加了一个关键产品. Collegium buys AZSTARYS ADHD drug for $650M, adding a key product to its portfolio.

科利吉亚制药公司同意从Corium Therapeutics以6.5亿美元的价格收购AZSTARYS,一种ADHD药物, 可能还要支付高达1.35亿美元. Collegium Pharmaceutical agreed to acquire AZSTARYS, an ADHD medication, from Corium Therapeutics for $650 million, with potential additional payments of up to $135 million. 该交易预计将于2026年第二季度完成,为Collegium的投资组合增加每天一次的ADHD治疗方案,补充其现有的Jornay PM. The deal, expected to close in Q2 2026, adds a once-daily ADHD treatment to Collegium’s portfolio, complementing its existing Jornay PM. 预计AZSTARYS在2025年产生超过76万份处方,并在2026年下半年带来5000多万美元的净收入并将收入延伸到2030年代. AZSTARYS, which generated over 760,000 prescriptions in 2025, is projected to bring more than $50 million in net revenue in the second half of 2026 and extend revenue into the 2030s. 这笔收购由现金和延期提款期限贷款资助,预计将立即增值,净杆率约为调整后EBITDA的两倍. The acquisition, funded by cash and a delayed-draw term loan, is expected to be immediately accretive, with a net leverage ratio of about two times adjusted EBITDA. 科利希姆预计将实现长期增长和运营效率,并更新2026年指导方针. Collegium anticipates long-term growth and operational efficiencies, with updated 2026 guidance to follow post-close.